Lidocaine Hydrochloride Topical Solution Recalled for Superpotency
Teligent Pharma is recalling Lidocaine Hydrochloride Topical Solution USP 4% due to superpotency. The affected lot was distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. Superpotency in a topical anesthetic represents a manufacturing deviation that could affect efficacy or safety, but without evidence of actual harm, it falls under moderate severity precautionary recalls.
Plain-English summary
Teligent Pharma, Inc. is recalling Lidocaine Hydrochloride Topical Solution USP, 4% (40 mg/mL), packaged in 50 mL screw cap bottles. The product is a prescription topical anesthetic manufactured by Teligent Pharma, Inc. in Buena, NJ, and distributed by McKesson Corporation dba Sky Packaging. The recall affects 7,176 bottles of lot #15594 with an expiration date of 05/2023.
The product is being recalled due to superpotency. The affected lot was distributed to a wholesaler in Colorado, who further distributed it nationwide in the USA.
Consumers and healthcare providers who have received this product should stop use and contact their healthcare provider with any questions or concerns. The NDC number for the recalled product is 63739-997-64.
The recalled product
- Product
- LIDOCAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
- Brand
- LIDOCAINE HYDROCHLORIDE
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Anesthetic
- Hazard
- superpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 15594
- Exp Date 05/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LIDOCAINE HYDROCHLORIDE
- SevereLidocaine Hydrochloride Topical Solution recalled for being superpotent
FDA (Drugs) · 2022-01-05
- ModerateLidocaine Hydrochloride Topical Solution Recalled for Superpotency
FDA (Drugs) · 2021-12-22
- CriticalPfizer Lidocaine and Bupivacaine Injection Label Mix-Up Recall
FDA (Drugs) · 2021-06-09
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowBusulfan Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-05-27
- SevereMG217 Multi-Symptom Treatment Cream recalled for microbial contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27